Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease
Despite being studied in clinical trials, CETP inhibitors are not yet an approved treatment for coronary heart disease. Here, by analyzing results from clinical trials and drug target mendelian randomization studies, the authors demonstrate that previous failure of CETP inhibitors are likely compoun...
Saved in:
Main Authors: | Amand F. Schmidt, Nicholas B. Hunt, Maria Gordillo-Marañón, Pimphen Charoen, Fotios Drenos, Mika Kivimaki, Deborah A. Lawlor, Claudia Giambartolomei, Olia Papacosta, Nishi Chaturvedi, Joshua C. Bis, Christopher J. O’Donnell, Goya Wannamethee, Andrew Wong, Jackie F. Price, Alun D. Hughes, Tom R. Gaunt, Nora Franceschini, Dennis O. Mook-Kanamori, Magdalena Zwierzyna, Reecha Sofat, Aroon D. Hingorani, Chris Finan |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/60544e33b7ec4a46bdebdd316f81bb1d |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk.
by: Audrey C Papp, et al.
Published: (2012) -
Genetic drug target validation using Mendelian randomisation
by: Amand F. Schmidt, et al.
Published: (2020) -
Oral health and all-cause, cardiovascular disease, and respiratory mortality in older people in the UK and USA
by: Eftychia Kotronia, et al.
Published: (2021) -
A sex-specific evolutionary interaction between ADCY9 and CETP
by: Isabel Gamache, et al.
Published: (2021) -
Roles of Cholesteryl-α-Glucoside Transferase and Cholesteryl Glucosides in Maintenance of <named-content content-type="genus-species">Helicobacter pylori</named-content> Morphology, Cell Wall Integrity, and Resistance to Antibiotics
by: Majjid A. Qaria, et al.
Published: (2018)